A widely used PSA threshold for recommending prostate biopsy (4.0 ng/mL) has remained unchanged over time despite some calls to lower the threshold, according to researchers. Steven B. Zeliadt, PhD, ...

Prostate cancer is the most common form of cancer among men in England, with cases surging by 25 per cent between 2019 and 2023, according to NHS data. It’s also the second-deadliest form of the ...

Employing MRI-targeted biopsy instead of systematic biopsy reduces overdiagnosis of low-grade prostate cancer by more than half, although diagnoses may be delayed among a small minority of patients ...

It may be appropriate to drop cutpoint from 4.0 to 2.0-2.5 ng/mL in men younger than 50 years. Diagnostic PSA levels in men younger than 50 years are significantly lower than guidelines suggest, ...

The global statistics are terrifying. Prostate cancer is the fourth most common cancer in all populations, the second most common cancer among men worldwide, and ranks first in Europe, where a third ...

Elevated PSA with a negative biopsy What is the next step in the treatment of a patient who has a prostate-specific antigen (PSA) level between 4 and 10 ng/mL and a negative biopsy?— Jack W. Spitzberg ...

Editor's note: Dr. Jamin Brahmbhatt is a urologist and robotic surgeon with Orlando Health and an assistant professor at the University of Central Florida’s College of Medicine.When I learned that ...

Nearly 300 abstracts on prostate cancer research from around the world will be presented at the European Association of Urology Congress (EAU26), taking place in London from 13–16 March 2026.

Dear Dr. Roach: A very healthy male friend in his upper 50s has to make a decision whether to accept or decline his very aggressive urologist’s decision to do a biopsy of his prostate. It seems that ...